Demirkan Faith, Akarsu Mesut, Sifil Aykut, Tutucu Kutlay Naci
Dokuz Eylul University School of Medicine, Department of Medicine, Division of Hematology/Oncology, Izmir, Turkey.
Nephron. 2002 May;91(1):162-3. doi: 10.1159/000057620.
We investigated the systemic effect of intraperitoneal low-molecular-weight heparin (LMWH) in continuous ambulatory peritoneal dialysis (CAPD) patients by measuring plasma total tissue factor pathway inhibitor (TFPI) levels, regarding the fact that the levels of plasma TFPI increases 2- to 4-fold after subcutaneous and intravenous administration of unfractioned heparin or LMWH. Eleven men and 6 women who had been on CAPD for 32 +/- 26 months and 15 healthy controls were included in the study. After administration of intraperitoneal enoksiparin in dialysate, plasma samples were obtained 4 h later. TFPI levels were significantly higher in CAPD patients (207.8 +/- 55 ng/ml) compared to the healthy subjects (72.5 +/- 29 ng/ml) (p < 0.0001). Both TFPI levels (225.9 +/- 47 vs. 207.8 +/- 55 ng/ml) (p < 0.54) and plasma factor Xa (anti-FXa assay) (0.097 +/- 0.14 vs. 0.093 +/- 0.16 U/ml) (p < 0.54) levels did not show any statistical difference before and after intraperitoneal administration of LMWH. By these findings we might suggest that intraperitoneal LMWH does not have any systemic effect.
鉴于皮下和静脉注射普通肝素或低分子量肝素(LMWH)后血浆组织因子途径抑制物(TFPI)水平会升高2至4倍,我们通过测量血浆总TFPI水平,研究了腹腔内注射LMWH对持续性非卧床腹膜透析(CAPD)患者的全身影响。该研究纳入了11名男性和6名女性CAPD患者,他们接受CAPD治疗的时间为32±26个月,另有15名健康对照者。在透析液中腹腔注射依诺肝素后,4小时后采集血浆样本。与健康受试者(72.5±29 ng/ml)相比,CAPD患者的TFPI水平显著更高(207.8±55 ng/ml)(p<0.0001)。腹腔内注射LMWH前后,TFPI水平(225.9±47 vs. 207.8±55 ng/ml)(p<0.54)和血浆因子Xa(抗FXa测定)水平(0.097±0.14 vs. 0.093±0.16 U/ml)(p<0.54)均未显示出任何统计学差异。根据这些发现,我们可能会认为腹腔内注射LMWH没有任何全身影响。